Puberty Blocker Trial Paused in England Amid Safety Concerns
A government-backed clinical trial investigating the use of puberty blockers for children and young people experiencing gender incongruence has been paused following new concerns raised by the Medicines and Healthcare products Regulatory Agency (MHRA), the UK’s medicines regulator. The move comes after the landmark Cass Review highlighted weaknesses in the evidence base for these treatments.
Trial Details and Concerns
The PATHWAYS trial, sponsored by King’s College London, aimed to study the effects of puberty-suppressing drugs in young people questioning their gender. Recruitment, which included consideration of children as young as 10, will not begin until the MHRA’s concerns are addressed. The Department of Health and Social Care confirmed that the concerns are “directly related to the wellbeing of children and young people.”
Discussions between the MHRA and King’s College London are scheduled to begin next week to resolve the issues. A Department of Health and Social Care spokesperson stated that the trial will only proceed if expert scientific and clinical evidence confirms its safety and necessity. Read the official press release here.
Context of the Cass Review and Recent Policy Changes
The pause in the PATHWAYS trial follows the publication of the Cass Review, commissioned by the previous government and accepted by the current one. The review found the evidence supporting the use of puberty blockers in gender medicine to be weak and recommended restricting their use outside of formal research settings.
Health Secretary Wes Streeting has since announced an indefinite ban on the routine prescription of puberty blockers for gender incongruence, limiting their availability to research contexts. The PATHWAYS trial was intended to generate the scientific evidence needed to inform future policy decisions.
Opposition and Ongoing Scrutiny
The trial has faced significant opposition from clinicians and campaigners, with over 380 health professionals signing a letter expressing concerns about its scientific and ethical foundations. A petition to halt the trial also garnered enough signatures to trigger a parliamentary debate. A potential judicial review challenge to the trial is also ongoing, but the Department of Health and Social Care has requested a pause in the legal process even as the MHRA’s concerns are examined.
Expert Reaction
Dr. Louise Irvine, co-chair of the Clinical Advisory Network on Sex and Gender (CAN-SG), welcomed the pause but emphasized the need for transparency. She stated that previous requests for scientific review were not met with sufficient evidence regarding the trial’s approval process.
Dr. Irvine also highlighted concerns that the trial did not adequately weigh the risks against the uncertain benefits of puberty blockers, noting that these treatments are rarely used in isolation and are typically part of a broader process potentially leading to irreversible interventions. She also pointed to concerns about the patient information sheets provided to families, which she believes did not fully explain the potential risks.
Looking Ahead
The pause in the PATHWAYS trial underscores the complex and evolving landscape of gender medicine. The outcome of the discussions between the MHRA and King’s College London will be crucial in determining the future of this research and the availability of puberty blockers for young people experiencing gender incongruence in England.
The post NHS Puberty Blocker Trial Paused: Safety Concerns Raised by Regulator appeared first on Archynewsy.